Myocardial osteopontin expression coincides with the development of heart failure

Hypertension

Volumn 33, Issue 2, 1999, Pages 663-670

  Singh, Krishna ^a   Sirokman, Geza ^a   Communal, Catherine ^a   Robinson, Kathleen G ^a   Conrad, Chester H ^a   Brooks, Wesley W ^a   Bing, Oscar H L ^a   Colucci, Wilson S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart; Heart failure; Hypertrophy; Inbred SHR; Osteopontin; Rats

Indexed keywords

OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE CELL; HYPERTENSION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0032998007     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.2.663     Document Type: Article

References (34)

1. Lorell B. Transition from hypertrophy to failure. Circulation. 1997;96: 3824-3827.
2. Brooks WW, Bing OHL, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effects of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation. 1997;96: 4002-4010.
3. Boluyt MO, Bing OHL, Lakatta EG. The aging spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Eur Heart J. 1996;16(suppl N):19-30.
4. Mitchell GF, Pfeffer JM, Pfeffer MA. The transition to failure in the spontaneously hypertensive rat. Am J Physiol. 1997;10:120S-126S.
5. Bing OHL, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol. 1995;27:383-396.
6. Bing OHL, Ngo HQ, Humphries DE, Robinson KG, Lucey EC, Carver W, Brooks WW, Conrad CH, Hayes JA, Goldstein RH. Localization of α(I) collagen mRNA in myocardium from the spontaneously hypertensive rat during the transition from compensated hypertrophy to failure. J Mol Cell Cardiol. 1997;29:2335-2344.
7. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91:161-170.
8. Boluyt MO, O'Neill L, Meredith AL, Bing OHL, Brooks WW, Conrad CH, Crow MT, Lakatta EG. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Circ Res. 1994; 75:23-32.
9. Sirokman G, Humphries DE, Bing OHL. Endogenous retroviral transcripts in myocytes from spontaneously hypertensive rats. Hypertension. 1997;30:88-93.
10. Singh K, Balligand J-L, Fischer TF, Smith TW, Kelly RA. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells: role in regulation of inducible nitric oxide synthase. J Biol Chem. 1995;270:28471-28478.
11. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7:1475-1482.
12. Giachelli CM, Schwartz, SM, Liaw L. Molecular and cellular biology of osteopontin: potential role in cardiovascular disease. Trends Cardiovasc Med. 1995;5:88-95.
13. Murry CE, Giachelli CM, Schwartz SM. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol. 1994;145: 1450-1462.
14. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan T-L, Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediates AII-induced DNA synthesis and collagen gel contraction. J Clin Invest. 1996;98:2218-2227.
15. Graf K, Do YS, Ashízawa N, Woemer MP, Giachelli CM, Marbe CC, Fleck E, Hsueh WA. Myocardial osteopontin is associated with left ventricular hypertrophy. Circulation. 1997;96:3063-3071.
16. Fanburg BL, Posner BI. Ribonucleic acid synthesis in experimental cardiac hypertrophy in rats. Circ Res. 1968;23:123-135.
17. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in spontaneously hypertensive rat. Proc Natl Acad Sci U S A. 1982;79:3310-3314.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
19. Singh K, Mukherjee AB, DeVouge M, Mukherjee BB. Differential processing of osteopontin transcripts in rat kidney- and osteoblast-derived cell lines. J Biol Chem. 1992;267:23847-23851.
20. Chen J, Singh K, Mukherjee BB, Sodek J. Developmental expression of osteopontin mRNA in rat tissues: evidence for a role for osteopontin in bone formation and resorption. Matrix. 1993;13:113-123.
21. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986;83:8819-8823.
22. Butler WT. The nature and significance of osteopontin. Connect Tissue Res. 1989;23:123-136.
23. Williams EB, Halpert I, Wickline S, Davidson G, Parks WC, Rottman JN. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation. 1995;92:705-709.
24. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB. Potential role of osteopontin and αvβ3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci U S A. 1997;94:9308-9313.
25. Kabour A, Henegar JR, Davineni VR, Janicki JS. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res. 1995;29:543-548.
26. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, Johnson RJ. Osteopontin expression in angiotensin II-mduced tubulointerstitial nephritis. Kidney Int. 1994;45:515-524.
27. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide and cGMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818.
28. Patarca R, Freeman GJ, Singh RP, Wei F, Durfee T, Blattner F, Regnier DC, Kozak CA, Mock BA, Morse HCI, Jerrells TR, Cantor H. Structural and functional studies of the early T lymphocyte activation 1 (Eta 1) gene: definition of a novel T cell dependent response associated with genetic resistance to bacterial infection. J Exp Med. 1989;170:145-161.
29. Balligand J-L, Ungrureanu D, Kelly RA, Kobzik L, Pimentai D, Michel T, Smith TW. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 1993;91:2314-2319.
30. Pinskey DJ, Cai B, Yang X, Rodriguez C, Scicca RR, Cannon PJ. The lethal effects of cytokine induced nitric oxide on cardiac myocytes are blocked by NOS antagonism or TGF-β. J Clin Invest. 1995;95:667-685.
31. Haywood GA, Tsao PS, Von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, Cooke JP, McKenna WJ, Fowler MB. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087-1094.
32. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of β-adrenergic inotropic responsiveness. Circulation. 1998;97:161-166.
33. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
34. Carver W, Molano I, Reaves TA, Borg TK, Terracio L. Role of the α1β1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol. 1995;165:425-437.